In a filing, Olema Pharmaceuticals Inc revealed its Officer Kovacs Shane William Charles acquired Company’s shares for reported $0.11 million on Jan 13 ’26. In the deal valued at $28.01 per share,3,822 shares were bought.
Then, Myles David C. bought 50,000 shares, generating $1,380,113 in total proceeds.
Before that, Myles David C. bought 10,000 shares. Olema Pharmaceuticals Inc shares valued at $283,363 were divested by the Officer at a price of $28.34 per share.
Piper Sandler initiated its Olema Pharmaceuticals Inc [OLMA] rating to an Overweight in a research note published on January 07, 2026; the price target was $40. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Citigroup also remained covering OLMA and reiterated its “Buy” recommendation on August 12, 2025. Goldman started covering the stock on April 02, 2024. It rated OLMA as “a Buy”.
Price Performance Review of OLMA
On Tuesday, Olema Pharmaceuticals Inc [NASDAQ:OLMA] saw its stock fall -3.13% to $27.89. Over the last five days, the stock has gained 11.38%. Olema Pharmaceuticals Inc shares have risen nearly 453.37% since the year began. Nevertheless, the stocks have risen 11.56% over the past one year.
How much short interest is there in Olema Pharmaceuticals Inc?
A steep rise in short interest was recorded in Olema Pharmaceuticals Inc stocks on 2025-12-31, dropping by -0.41 million shares to a total of 10.4 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 10.81 million shares. There was a decline of -3.96%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 30, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
